BridgeBio Pharma, Inc. (BBIO)
| Market Cap | 13.28B +22.7% |
| Revenue (ttm) | 713.07M +202.4% |
| Net Income | -691.87M |
| EPS | -3.57 |
| Shares Out | 195.49M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,292,328 |
| Open | 67.35 |
| Previous Close | 66.39 |
| Day's Range | 66.73 - 68.52 |
| 52-Week Range | 52.75 - 93.42 |
| Beta | 0.97 |
| Analysts | Strong Buy |
| Price Target | 108.27 (+59.36%) |
| Est. Earnings | Nov 2, 2026 |
About BBIO
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective ... [Read more]
Financial Performance
In 2025, BridgeBio Pharma's revenue was $502.08 million, an increase of 126.26% compared to the previous year's $221.90 million. Losses were -$724.93 million, 35.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for BBIO stock is "Strong Buy." The 12-month stock price target is $108.27, which is an increase of 59.36% from the latest price.
News
BridgeBio Pharma price target lowered to $102 from $104 at BofA
BofA analyst Jason Zemansky lowered the firm’s price target on BridgeBio Pharma (BBIO) to $102 from $104 and keeps a Buy rating on the shares. The firm updated estimates ahead…
BridgeBio Pharma price target raised to $120 from $115 at Piper Sandler
Piper Sandler raised the firm’s price target on BridgeBio Pharma (BBIO) to $120 from $115 and keeps an Overweight rating on the shares. Ahead of Q3 2026 earnings for the…
BridgeBio Pharma price target lowered to $91 from $94 at Citi
Citi lowered the firm’s price target on BridgeBio Pharma (BBIO) to $91 from $94 and keeps a Neutral rating on the shares. The firm updated the company’s model ahead the…
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic condi...
BridgeBio Pharma assumed with a Buy at UBS
UBS assumed coverage of BridgeBio Pharma (BBIO) with a Buy rating with a price target of $92, up from $82. The Street underestimates the company’s lead drug Attruby commercial potential…
BridgeBio Pharma presents results from Phase 3 CALIBRATE trial of encaleret
BridgeBio Pharma (BBIO) presented bone turnover results and patient-reported outcomes from the Phase 3 CALIBRATE trial of encaleret in autosomal dominant hypocalcemia type 1, ADH1. The data were prese...
BridgeBio Pharma price target lowered to $156 from $157 at Barclays
Barclays lowered the firm’s price target on BridgeBio Pharma (BBIO) to $156 from $157 and keeps an Overweight rating on the shares. The firm expects another quarter of steady strength…
BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026
PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on develo...
BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting
PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on develo...
BridgeBio Pharma announces FDA acceptance of oral infigratinib NDA
BridgeBio Pharma (BBIO) announced the FDA has accepted for filing its new drug application, or NDA, with Priority Review for oral infigratinib for the treatment of children with achondroplasia. The…
BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia
- Accepted for Priority Review with a PDUFA target action date of February 4, 2027; being granted Priority Review by the FDA underscores the significant unmet need for an oral targeted therapeutic opt...
BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day
- October 6 YouTube premiere featuring Sway Calloway, Howard “H” White and leading medical and cultural voices anchors community education nationwide
BridgeBio Pharma presents new data from interim analysis of FORTIFY study
BridgeBio Pharma (BBIO) presented new exploratory cardiac data from the 12-month interim analysis of FORTIFY, the Phase 3 clinical trial of oral BBP-418 in individuals living with limb-girdle muscular...
BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels
- In exploratory analyses at Month 12, among individuals with LGMD2I/R9 (FKRP-related) with elevated HS troponin I at baseline, 100% treated with BBP-418 returned to the normal range by Month 12 versu...
BridgeBio Pharma Transcript: Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
The forum highlighted a robust late-stage portfolio with four major product launches expected globally within 18 months, driven by strong clinical data and real-world evidence. Attruby leads with blockbuster sales and new data, while three additional therapies target high unmet needs and billion-dollar markets.
BridgeBio Pharma announces results from trial of tafamidis in ATTR-CM
BridgeBio Pharma (BBIO) announced results published in Cardiology and Therapy from the first peer-reviewed, contemporary real-world comparative effectiveness retrospective study of transthyretin, TTR,...
Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening
- In the first peer-reviewed, real-world, contemporary, comparative effectiveness study of TTR stabilizers in ATTR-CM using U.S. claims data, acoramidis was associated with a statistically and clinica...
BridgeBio Pharma Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
China-originated innovation and AI are driving operational improvements and partnerships, while regulatory wins and differentiated clinical data fuel strong growth for key products. Attruby leads with first-line market expansion and premium pricing, and multiple pipeline launches are set to drive profitability by 2028.
BridgeBio Pharma Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Multiple late-stage assets are nearing launch, with Attruby leading in ATTR-CM and strong differentiation supported by clinical and real-world data. BBP-418 and infigratinib show robust efficacy and market potential, while global commercialization is advancing with a solid financial base and strategic MFN agreement.
BridgeBio Pharma Transcript: Wells Fargo 21st Annual Healthcare Conference
The business is experiencing strong growth with Attruby and anticipates further acceleration from three major drug launches in 2027. Differentiation in ATTR-CM, robust pipeline data, and targeted launch strategies for rare diseases underpin confidence in sustained expansion and capital deployment for future innovation.
BridgeBio Pharma Slides: Corporate presentation
BridgeBio Pharma has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
BridgeBio Pharma presents new exploratory analyses from PROPEL 3 at ESPE
BridgeBio Pharma (BBIO) presented new exploratory analyses from PROPEL 3, the global Phase 3 study of oral infigratinib in children living with achondroplasia, showing directionally favorable trends b...
Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial
- Treatment with oral infigratinib for 52 weeks in PROPEL 3 resulted in favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media events
BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026
PALO ALTO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on devel...
BridgeBio Pharma files $500M mixed securities shelf
17:26 EDT BridgeBio Pharma (BBIO) files $500M mixed securities shelf